Gene · 140
Papers1,628
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 1,628
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A review of current therapeutics for psoriasis: Systemic and topical use of non-biological drugs. | Eur J Clin Pharmacol | 2026 | 41553544 | PubTator, text mining | PubMed |
| Inhibition of Retinal AdoRA2a Activity Attenuates Myopia Progression. | Invest Ophthalmol Vis Sci | 2026 | 41533917 | PubTator, text mining | PubMed |
| Long-Read Sequencing Reveals Cell- and State-Specific Alternative Splicing in 293T and A549 Cell Transcriptomes. | Int J Mol Sci | 2026 | 41516360 | PubTator, text mining | PubMed |
| Increased expression of the purinergic receptor P2Y6 in the bovine lung following experimental BRSV infection. | Vet Immunol Immunopathol | 2026 | 41485301 | PubTator, text mining | PubMed |
| Serpine2-Lrp1 and CD39-A3AR Intercellular Signalling Pathways: Novel Therapeutic Targets for Vascular Dementia. | Neurosci Bull | 2026 | 41350793 | PubTator, text mining | PubMed |
| Structure-activity relationship analysis of 5'-substituted C2-hexynyl-4'-thioadenosine analogs as dual A2A/A3 adenosine receptor agonists with tunable selectivity and anti-inflammatory activity. | Eur J Med Chem | 2026 | 41273796 | PubTator, text mining | PubMed |
| Narirutin Reprograms Fatty Acid Metabolism and Inhibits Tumorigenesis via Downregulating ADORA3 Expression in Colorectal Cancer. | J Gastroenterol Hepatol | 2026 | 41235759 | PubTator, text mining | PubMed |
| Inhibition of ADORA3 Accelerates Hematoma Resolution and Neurological Recovery after ICH. | Cerebrovasc Dis | 2026 | 41231737 | PubTator, text mining | PubMed |
| Discovery of a Novel Template, N3‑1'-Homologated 4'-Truncated Thiosugar-Substituted Xanthine as an A3AR Antagonist via Conversion of an A1AR Antagonist. | ACS Med Chem Lett | 2025 | 41404008 | PubTator, text mining | PubMed |
| Design, Synthesis, and Biological Evaluation of C2-(N-Substituted Amino) Truncated 4'-Thioadenosine Derivatives as A2AAR and A3AR Dual Ligands. | ACS Med Chem Lett | 2025 | 41404002 | PubTator, text mining | PubMed |
| Adenosine A3 Receptor and Its Potential Role in Cancer Treatment: A Narrative Review. | Cureus | 2025 | 41200621 | PubTator, text mining | PubMed |
| Combining network toxicology, machine learning and molecular docking to explore the mechanism of bisphenol A-induced Asthma. | Medicine (Baltimore) | 2025 | 41189187 | PubTator, text mining | PubMed |
| Caffeine-associated reduction in patent ductus arteriosus is mediated in part by adenosine receptor antagonism. | Am J Physiol Heart Circ Physiol | 2025 | 41165563 | PubTator, text mining | PubMed |
| Bitopic A3 Adenosine Receptor Molecular Probes: Positive Allosteric Modulation and Noncanonical Activation. | J Med Chem | 2025 | 41026931 | PubTator, text mining | PubMed |
| Structural Simplification from Tricyclic to Bicyclic Scaffolds: A Long-Term Investigation in the Field of Adenosine Receptor Antagonists. | Cells | 2025 | 41002445 | PubTator, text mining | PubMed |
| Cordycepin: A Promising Anticancer Compound from Traditional Chinese Medicine. | Am J Chin Med | 2025 | 40905224 | PubTator, text mining | PubMed |
| LINC00152 knockdown exerts repressive effects on epithelial-mesenchymal transition in bladder cancer. | Cytotechnology | 2025 | 40851931 | PubTator, text mining | PubMed |
| Molecular basis of ligand binding and receptor activation at the human A3 adenosine receptor. | Nat Commun | 2025 | 40825947 | Swiss-Prot, curated | PubMed |
| Dynamic shifts in trophoblast nucleos(t)ide metabolism, transport, and adenosine signaling during gestation and preterm birth. | Sci Rep | 2025 | 40825832 | PubTator, text mining | PubMed |
| Stromal Cells, Extracellular Matrix Components, and Adenosine A3 Receptor in Prostate Biopsies: Association With Histological Grade, PSA Levels, and Clinical Tumor Stage. | J Histochem Cytochem | 2025 | 40682346 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/140/papers?page=2